Zhifei Biological Products Approved to Begin China Phase III Trial of TB Vaccine

by Richard Daverman, PhD

January 11, 2013 -- Chongqing Zhifei Biological Product Co. has been granted SFDA approval to begin a Phase III trial of an existing product, Mycobacterium Vaccae for Injection (Vaccae), as a vaccine for tuberculosis, a currently unmet need. Vaccae is an immune system modulator that the company currently sells as an adjuvant to treat TB. More details....

Stock Symbol: (SHE: 300122)

Back to news